{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:45:50Z","timestamp":1790527550708,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005413","name":"Universite de Paris Faculte de Sante","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005413","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018737","name":"Laboratoire d'Excellence Inflamex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021716","name":"Universit\u00e9 de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021716","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jhep.2021.02.012","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T18:15:16Z","timestamp":1614017716000},"page":"1442-1454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Targeting cell-intrinsic metabolism for antifibrotic therapy"],"prefix":"10.1016","volume":"74","author":[{"given":"Helene","family":"Gilgenkrantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Mallat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-403X","authenticated-orcid":false,"given":"Richard","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0053-7807","authenticated-orcid":false,"given":"Sophie","family":"Lotersztajn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.02.012_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev.pharmtox.45.120403.095906","article-title":"Hepatic fibrosis: molecular mechanisms and drug targets","volume":"45","author":"Lotersztajn","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jhep.2021.02.012_bib2","doi-asserted-by":"crossref","first-page":"C789","DOI":"10.1152\/ajpcell.00230.2013","article-title":"Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis","volume":"305","author":"Mallat","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jhep.2021.02.012_bib3","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.2174\/13816128113199990344","article-title":"Pathophysiology of NASH: perspectives for a targeted treatment","volume":"19","author":"Marra","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhep.2021.02.012_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bbadis.2013.02.019","article-title":"Origins and functions of liver myofibroblasts","volume":"1832","author":"Lemoinne","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2021.02.012_bib6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2021.02.012_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s42255-018-0008-5","article-title":"Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis","volume":"1","author":"Zhao","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib9","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1126\/scisignal.aax4067","article-title":"Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-beta","volume":"12","author":"Yin","year":"2019","journal-title":"Sci Signal"},{"key":"10.1016\/j.jhep.2021.02.012_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","article-title":"Targeting metabolic dysregulation for fibrosis therapy","volume":"19","author":"Zhao","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2021.02.012_bib11","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2012.07.115","article-title":"Hedgehog controls hepatic stellate cell fate by regulating metabolism","volume":"143","author":"Chen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1053\/j.gastro.2020.03.008","article-title":"CPEB4 increases expression of PFKFB3 to induce glycolysis and activate mouse and human hepatic stellate cells, promoting liver fibrosis","volume":"159","author":"Mejias","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.ajpath.2020.08.002","article-title":"Pyruvate kinase M2 tetramerization protects against hepatic stellate cell activation and liver fibrosis","volume":"190","author":"Zheng","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2021.02.012_bib14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2017.12.022","article-title":"Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells","volume":"154","author":"Du","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1042\/bj3350697","article-title":"De novo expression of glutamine synthetase during transformation of hepatic stellate cells into myofibroblast-like cells","volume":"335","author":"Bode","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.jhep.2021.02.012_bib16","article-title":"Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.02.012_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcmgh.2019.12.006","article-title":"Increased glutaminolysis marks active scarring in nonalcoholic steatohepatitis progression","volume":"10","author":"Du","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.cmet.2019.08.001","article-title":"Glutamate signaling in hepatic stellate cells drives alcoholic steatosis","volume":"30","author":"Choi","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib19","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.31194","article-title":"Glutamate signaling in alcohol-associated fatty liver: \"Pas de Deux\"","volume":"72","author":"Mallat","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","article-title":"Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation","volume":"73","author":"Bates","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","article-title":"Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation","volume":"26","author":"Kim","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib23","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2017.01.021","article-title":"Stearoyl-CoA desaturase promotes liver fibrosis and tumor development in mice via a Wnt positive-signaling loop by stabilization of low-density lipoprotein-receptor-related proteins 5 and 6","volume":"152","author":"Lai","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/hep4.1107","article-title":"Role of Aramchol in steatohepatitis and fibrosis in mice","volume":"1","author":"Iruarrizaga-Lejarreta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jhep.2021.02.012_bib26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.gastro.2011.09.049","article-title":"A\u00a0high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells","volume":"142","author":"Teratani","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2014.03.018","article-title":"Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells","volume":"61","author":"Tomita","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib28","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/hep4.1395","article-title":"PNPLA3 I148M variant impairs liver X receptor signaling and cholesterol homeostasis in human hepatic stellate cells","volume":"3","author":"Bruschi","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib29","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm.3704","article-title":"De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells","volume":"20","author":"Berod","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2021.02.012_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.bbrc.2015.06.023","article-title":"Succinate causes alpha-SMA production through GPR91 activation in hepatic stellate cells","volume":"463","author":"Li","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib31","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1074\/jbc.M115.692244","article-title":"Sirtuin 3 (SIRT3) regulates alpha-smooth muscle actin (alpha-SMA) production through the succinate dehydrogenase-G protein-coupled receptor 91 (GPR91) pathway in hepatic stellate cells","volume":"291","author":"Li","year":"2016","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.02.012_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41590-019-0372-7","article-title":"SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity","volume":"20","author":"Keiran","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2021.02.012_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.02.012_bib34","doi-asserted-by":"crossref","first-page":"E3186","DOI":"10.1073\/pnas.1119964109","article-title":"Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis","volume":"109","author":"Ramachandran","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2021.02.012_bib35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A\u00a0guide to immunometabolism for immunologists","volume":"16","author":"O'Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2021.02.012_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41590-019-0407-0","article-title":"Metabolic adaptations of tissue-resident immune cells","volume":"20","author":"Caputa","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2021.02.012_bib37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.12997\/jla.2020.9.2.231","article-title":"Metabolic reprogramming of macrophages in atherosclerosis: is it all about cholesterol?","volume":"9","author":"Yvan-Charvet","year":"2020","journal-title":"J\u00a0Lipid Atheroscler"},{"key":"10.1016\/j.jhep.2021.02.012_bib38","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.addr.2009.03.011","article-title":"Transcriptional regulation of hepatic stellate cells","volume":"61","author":"Mann","year":"2009","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jhep.2021.02.012_bib39","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/liv.12170","article-title":"Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation","volume":"33","author":"Bieghs","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.02.012_bib40","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1053\/j.gastro.2010.02.051","article-title":"Role of scavenger receptor A and CD36 in diet-induced nonalcoholic steatohepatitis in hyperlipidemic mice","volume":"138","author":"Bieghs","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.02.028","article-title":"Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis","volume":"57","author":"Leroux","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/gutjnl-2018-316137","article-title":"Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver","volume":"68","author":"Habib","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.02.012_bib43","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1194\/jlr.M093369","article-title":"Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption","volume":"60","author":"Tardelli","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhep.2021.02.012_bib44","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.30929","article-title":"Monoacylglycerol lipase inhibition protects from liver injury in mouse models of sclerosing cholangitis","volume":"71","author":"Tardelli","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cmet.2018.10.015","article-title":"Hepatocyte-macrophage acetoacetate shuttle protects against tissue fibrosis","volume":"29","author":"Puchalska","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nri.2017.99","article-title":"The spectrum of T cell metabolism in health and disease","volume":"18","author":"Bantug","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2021.02.012_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cmet.2020.09.004","article-title":"The gut microbiota at the service of immunometabolism","volume":"32","author":"Michaudel","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib49","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/s41467-018-04450-y","article-title":"Mucosal-associated invariant T cells are a profibrogenic immune cell population in the liver","volume":"9","author":"Hegde","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib50","first-page":"3755","article-title":"Mucosal-associated invariant T cells and disease","volume":"11","author":"Toubal","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2021.02.012_bib51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41556-020-0511-2","article-title":"FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome","volume":"22","author":"Li","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jhep.2021.02.012_bib52","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.02.012_bib53","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"Ibrahim","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.02.012_bib54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.02.012_bib55","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","article-title":"Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis","volume":"22","author":"Xia","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhep.2021.02.012_bib56","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","author":"Thangapandi","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.02.012_bib57","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A\u00a0genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2021.02.012_bib58","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib59","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1038\/ncomms12757","article-title":"MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C","volume":"7","author":"Thabet","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib60","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.29064","article-title":"The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib61","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.29025","article-title":"Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis","volume":"65","author":"McCommis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib62","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib63","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2019.01.026","article-title":"Autophagy in liver diseases: time for translation?","volume":"70","author":"Allaire","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib64","doi-asserted-by":"crossref","first-page":"C263","DOI":"10.1152\/ajpcell.00295.2016","article-title":"Autophagy in chronic liver diseases: the two faces of Janus","volume":"312","author":"Gual","year":"2017","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jhep.2021.02.012_bib65","doi-asserted-by":"crossref","first-page":"869390","DOI":"10.1155\/2014\/869390","article-title":"Autophagy: a multifaceted partner in liver fibrosis","volume":"2014","author":"Mallat","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2021.02.012_bib66","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jhep.2014.04.043","article-title":"Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy","volume":"61","author":"Ni","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib67","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jhep.2019.10.028","article-title":"A\u00a0defect in endothelial autophagy occurs in patients with non-alcoholic steatohepatitis and promotes inflammation and fibrosis","volume":"72","author":"Hammoutene","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib68","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/15548627.2015.1058473","article-title":"Macrophage autophagy protects against liver fibrosis in mice","volume":"11","author":"Lodder","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.jhep.2021.02.012_bib69","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8523","article-title":"LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling","volume":"12","author":"Wan","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2021.02.012_bib70","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2011.12.044","article-title":"Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues","volume":"142","author":"Hernandez-Gea","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib71","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jhep.2011.07.010","article-title":"A\u00a0role for autophagy during hepatic stellate cell activation","volume":"55","author":"Thoen","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib72","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jhep.2020.04.044","article-title":"Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis","volume":"73","author":"Gao","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib73","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0016-5085(99)70406-3","article-title":"Rapamycin inhibits hepatic stellate cell proliferation in\u00a0vitro and limits fibrogenesis in an in\u00a0vivo model of liver fibrosis","volume":"117","author":"Zhu","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib74","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1126\/science.1190354","article-title":"An\u00a0autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis","volume":"329","author":"Hidvegi","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jhep.2021.02.012_bib75","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1073\/pnas.1821022116","article-title":"Ferroptosis as a target for protection against cardiomyopathy","volume":"116","author":"Fang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhep.2021.02.012_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12950-019-0216-0","article-title":"Ferroptosis inhibitor alleviates Radiation-induced lung fibrosis (RILF) via down-regulation of TGF-beta1","volume":"16","author":"Li","year":"2019","journal-title":"J\u00a0Inflamm (Lond)"},{"key":"10.1016\/j.jhep.2021.02.012_bib77","article-title":"Inhibiting xCT\/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells and protects against liver fibrosis","author":"Du","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhep.2021.02.012_bib78","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/iub.1895","article-title":"P53-dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride-induced liver fibrosis and hepatic stellate cell activation","volume":"71","author":"Wang","year":"2019","journal-title":"IUBMB Life"},{"key":"10.1016\/j.jhep.2021.02.012_bib79","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/JLB.3A0318-108R","article-title":"Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis","volume":"105","author":"Handa","year":"2019","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.jhep.2021.02.012_bib80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41419-019-1678-y","article-title":"Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis","volume":"10","author":"Tsurusaki","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jhep.2021.02.012_bib81","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear receptors, RXR, and the big bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2021.02.012_bib82","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.3390\/ijms20205045","article-title":"Liver X receptors regulate cholesterol metabolism and immunity in hepatic nonparenchymal cells","volume":"20","author":"Endo-Umeda","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2021.02.012_bib83","doi-asserted-by":"crossref","first-page":"21309","DOI":"10.1038\/srep21309","article-title":"Liver X receptor alpha is essential for the capillarization of liver sinusoidal endothelial cells in liver injury","volume":"6","author":"Xing","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2021.02.012_bib84","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2010.11.053","article-title":"Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease","volume":"140","author":"Beaven","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib85","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/hep.28406","article-title":"Activation of liver X receptor\/retinoid X receptor pathway ameliorates liver disease in Atp7B(-\/-) (Wilson disease) mice","volume":"63","author":"Hamilton","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib86","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.celrep.2018.12.094","article-title":"Impaired LXRalpha phosphorylation attenuates progression of fatty liver disease","volume":"26","author":"Becares","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2021.02.012_bib87","first-page":"577833","article-title":"Liver X receptor b controls hepatic stellate cell activation via Hedgehog Signaling","author":"Zhong","year":"2019","journal-title":"bioRxiv"},{"key":"10.1016\/j.jhep.2021.02.012_bib88","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib89","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib90","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2021.02.012_bib91","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jhep.2021.02.012_bib92","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.02.012_bib93","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2016.12.005","article-title":"The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction","volume":"66","author":"Schwabl","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib94","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib95","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPARalpha activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodriguez-Vilarrupla","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib96","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib97","doi-asserted-by":"crossref","first-page":"40650","DOI":"10.1074\/jbc.M510094200","article-title":"Peroxisome proliferator-activated receptor gamma suppresses proximal alpha1(I) collagen promoter via inhibition of p300-facilitated NF-I binding to DNA in hepatic stellate cells","volume":"280","author":"Yavrom","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhep.2021.02.012_bib98","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2020.01.027","article-title":"Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib99","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in\u00a0vivo and in\u00a0vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib101","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib102","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib103","doi-asserted-by":"crossref","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A\u00a0randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"Francke","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2021.02.012_bib104","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jhep.2021.02.012_bib105","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.02.012_bib106","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1136\/gutjnl-2019-319104","article-title":"Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges","volume":"69","author":"Dufour","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.02.012_bib107","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.02.012_bib108","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2021.02.012_bib109","doi-asserted-by":"crossref","first-page":"105889","DOI":"10.1016\/j.cct.2019.105889","article-title":"A\u00a0randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88","author":"Pedrosa","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhep.2021.02.012_bib110","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jhep.2011.04.008","article-title":"Targeted therapy of liver fibrosis\/cirrhosis and its complications","volume":"55","author":"Poelstra","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.02.012_bib111","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2021.02.012_bib112","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhep.2021.02.012_bib113","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice","volume":"54","author":"Bansal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.02.012_bib114","doi-asserted-by":"crossref","DOI":"10.3390\/nano10101945","article-title":"Recent advances in nanomedicine for the diagnosis and therapy of liver fibrosis","volume":"10","author":"Bai","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.jhep.2021.02.012_bib115","first-page":"364","article-title":"Therapeutic targeting of liver inflammation and fibrosis by nanomedicine","volume":"3","author":"Bartneck","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.jhep.2021.02.012_bib116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biomaterials.2019.03.025","article-title":"Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in\u00a0vivo","volume":"206","author":"Ergen","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.jhep.2021.02.012_bib117","first-page":"260","article-title":"No anti-fibrotic effect of selonsertib in NASH","volume":"17","author":"Dickson","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821001124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:40:21Z","timestamp":1759174821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821001124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":117,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0168827821001124"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.02.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cell-intrinsic metabolism for antifibrotic therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}